Recent Publications
- Keegan, B.; Blagg, B. A Split Renilla Luciferace Complementation Assay for the Evaluation of Hsp90/Aha1 Complex Disruptors and Their Activity at the Aha1 C-Terminal Domain. ACS Chemical Biology. 2022
- Mishra, S. J.; Reynolds, T. S.; Merfeld, T.; Balch, M.; Peng, S.; Deng, J.; Matts, R.; Blagg, B. S. J. Structure-Activity Relationship Study of Tertiary Alcohol Hsp90α-Selective Inhibitors with Novel Binding Mode. ACS Med. Chem. Lett. 2022, 13, 12, 1870-1878.
- Dou, X.; Patel, B. A.; D'Amico, T.; Subramanian, C.; Cousineau, E.; Yi, Y.; Cohen, M.; Blagg, B. S. J. Synthesis and Evaluation of Simplified Cruentaren A Analogues. J. Org. Chem. 2022, 87, 15, 9940-9956.
- Pugh, K. W.; Alnead, M.; Brackett, C. M.; Blagg, B. S. J. The Biology an Inhibition of Glucose-Regulated Protein 94/gp96. Med. Res. Rev. 2021, 42(6), 2007-2024.
- Meka, P. N.; Amatya, E.; Kaur, S.; Banerjee, M., Zuo, A.; Dobrowski, R. T.; Blagg, B. S. J. Synthesis and Evaluation of 3'- and 4'-Substituted Cyclohexyl Noviomimetics that Modulate Mitochondrial Respiration. Bioorg. & Med. Chem. 2022 70, 116940.
- Keegan, B. M.; Catalfano, K. C.; Banerjee, M.; Blagg, B. S. J. Synthesis and Evaluation of Small Molecule Disruptors of the Aha1/ Hsp90 Complex for the Reduction of Tau Aggregation. ACS Med. Chem. Lett. 2022 13, 827-832.
- Kurop, M. K., Hyuen, C. M.; Kelly, J. H.; Blagg, B. S. J. The Heat Shock Response and Small Molecule Regulators. Our, J. Med. Chem. 2021 226:113846.
- Chaudhury, S.; Meka, P. N.; Banerjee, M.; Kent, C. N.; Blagg, B. S. J. Structure-Based Design, Synthesis, and Biological Evaluation of Hsp90β-Selective Inhibitors. Chemistry 2021 27(59):14747-14764.
- Banerjee, M.; Hatial, I.; Keegan, B. M.; Blagg, B. S. J. Assay Design and Development Strategies for Finding Hsp90 Inhibitors and Their Role in Human Diseases. Pharmacy. Ther. 2021 221:107747.
- Mishra, S. J.; Khandelwal, A.; Banerjee, M.; Balch, M; Peng, S.; Davis. R. E.; Merfeld, T.; Munthali, V.; Deng, J.; Matts, R. L.; Blagg, B. S. J. Selective Inhibition of the Hsp90α Isoform. Angew. Chem. Int. Ed. Engl. 2021 60(19):10547-10551.
- Serwetnyk, M. A.; Blagg, B. S. J. The Disruption of Protein-Protein Interactions with Co-Chaperones and Client Substrates as a Strategy Towards Hsp90 Inhibition. Acta. Pharm. Sin. B. 2021 11(6):1446-1468.
- Patel, B. A.; D'Amico, T. L.; Blagg, B. S. J. Natural Products and Other Inhibitors of F1FOATP Synthase. Eur. J. Med. Chem. 2020 207, 112779.
- Chaudhury, S.; Keegan, B. M.; Blagg, B. S. J. The Role and Therapeutic Potential of Hsp90, Hsp70, and Smaller Heat Shock Proteins in Peripheral and Central Neuropathies. Med. Res. Rev. 2021 41(1): 202-222.
- Pugh, K. W.; Zhang, Z.; Wang, J.; Xu, X.; Munthali, V.; Zuo, A.; Blagg, B. S. J. From Bacteria to Cancer: A Benzothiazole-Based DNA Gyrase B Inhibitor Redesigned for Hsp90 C-Terminal Inhibition. ACS Med. Chem. Lett. 2020 11, 8, 1535-1538.
- Stine, C.; Coleman, D. L.; Flohrschutz, A. T.; Thompson, A. L.; Mishra, S.; Blagg, B. S.; Largent-Milnes, T. M.; Lei, W.; Streicher, J. M. Heat Shock Protein 90 Inhibitors Block the Antinociceptive Effects of Opioids in Mouse Chemotherapy-Induced Neuropathy and Cancer Bone Pain Models. PAIN 2020 161(8):1798-1807.
- Lei, W. Duron, D. I.; Stine, C.; Mishra, S.; Blagg, B. S. J.; Streicher, J. M. The Alpha Isoform of Heat Shock Protein 90 and the Co-chaperones p23 and Cdc37 Promote Opioid Anti-nociception in the Brain. Front. Mol. Neurosci., 2019 12:294.
- Zhang, Z.; Banerjee, M.; Davis, R. E.; Blagg, B. S. J. Mitochondrial Targeted-Hsp90 Inhibitors that Manifest Anticancer Activities. Bioorg. Med. Chem. Lett., 2019 29(22):126676.
- Khandelwal, A.; Kent, C. N.; Balch, M.; Peng, S.; Mishra, S. J.; Deng, J.; Day, V. W.; Liu, W.; Subramanian, C.; Cohen, M.; et al. Structure-Guided Design of an Hsp90β N-Terminal Isoform-Selective Inhibitor. Nat. Commun. 2018, 9 (1), 425.
- Forsberg, L. K.; Anyika, M.; You, Z.; Emery, S.; McMullen, M.; Dobrowsky, R. T.; Blagg, B. S. J. Development of Noviomimetics That Modulate Molecular Chaperones and Manifest Neuroprotective Effects. Eur. J. Med. Chem. 2018, 143, 1428–1435.
- Que, N. L. S.; Crowley, V. M.; Duerfeldt, A. S.; Zhao, J.; Kent, C. N.; Blagg, B. S. J.; Gewirth, D. T. Structure Based Design of a Grp94-Selective Inhibitor: Exploiting a Key Residue in Grp94 To Optimize Paralog-Selective Binding. J. Med. Chem. 2018, 61 (7), 2793–2805.
- Shelton, L. B.; Baker, J. D.; Zheng, D.; Sullivan, L. E.; Solanki, P. K.; Webster, J. M.; Sun, Z.; Sabbagh, J. J.; Nordhues, B. A.; Koren, J.; et al. Hsp90 Activator Aha1 Drives Production of Pathological Tau Aggregates. Proc. Natl. Acad. Sci. 2017, 114 (36), 9707–9712.
- Byrd, K. M.; Kent, C. N.; Blagg, B. S. J. Synthesis and Biological Evaluation of Stilbene Analogues as Hsp90 C-Terminal Inhibitors. ChemMedChem 2017, 12 (24), 2022–2029.
- Khandelwal, A.; Crowley, V. M.; Blagg, B. S. J. Natural Product Inspired N-Terminal Hsp90 Inhibitors: From Bench to Bedside? Med. Res. Rev. 2016, 36 (1), 92–118.
- Byrd, K. M.; Subramanian, C.; Sanchez, J.; Motiwala, H. F.; Liu, W.; Cohen, M. S.; Holzbeierlein, J.; Blagg, B. S. J. Synthesis and Biological Evaluation of Novobiocin Core Analogues as Hsp90 Inhibitors. Chem. - Eur. J. 2016, 22 (20), 6921–6931.
- Hall, J. A.; Seedarala, S.; Zhao, H.; Garg, G.; Ghosh, S.; Blagg, B. S. J. Novobiocin Analogues That Inhibit the MAPK Pathway. J. Med. Chem. 2016, 59 (3), 925–933.